Insulin pump therapy, often referred to as continuous subcutaneous insulin infusion (CSII), is an alternate method of insulin administration for persons who require multiple daily injections (MDI) for treatment of diabetes. The concept in insulin pump therapy was first introduced by Arnold Kadish in Beverly Hills, CA, in the 1960s. However, it was not until the early 1980s that the first FDA-approved pump became available for use by people with type 1 diabetes.
The basic design of pumps is that a syringe-driven pump uses a subcutaneously placed catheter to deliver insulin that is controlled by electronics within the pump (Skyler, 2010). The insulin used in pumps is rapid-acting insulin (regular insulin or more recently the insulin analogs: Novolog, Humalog, Apidra). Insulin pumps provide the most physiologic method for delivery of insulin. In nondiabetic people, the pancreas secretes background insulin throughout the day...
References and Readings
- Skyler, J. S. (2010). Continuous subcutaneous insulin infusion – An historical perspective. Diabetes Technology & Therapeutics, 12(Suppl. 1), S5–S7.Google Scholar
- The Diabetes Control and Complications Trial Research Group. (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. New England Journal of Medicine, 329, 977–986.CrossRefGoogle Scholar